Proposed clinical model for predicting speech outcomes in patients undergoing Furlow palatoplasty for velopharyngeal insufficiency after primary palatoplasty
Journal of Cranio-Maxillofacial Surgery · 2024
DOI: 10.1016/j.jcms.2023.12.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cranio-Maxillofacial Surgery, 2024. Verfasst von Zhongping Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases and Department of Oral and Maxillofacial Surgery, West Ch…. Hauptthemen laut MEDLINE: Velopharyngeal Insufficiency, Cleft Palate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Sichuan Province Science and Technology Support Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
This study aimed to validate the predictors of speech outcomes following Furlow palatoplasty in patients with velopharyngeal insufficiency (VPI) after primary palatoplasty and to propose and validate a model to predict the risk of persistent VPI. The study included patients with VPI after primary palatoplasty who underwent Furlow palatoplasty as a secondary surgery. Eleven variables were included: velar length, pharyngeal cavity depth, velopharyngeal gap, velopharyngeal closure pattern, sex, presence of cleft lip, existence of palatal fistula, surgeon, age at primary palatoplasty, age at secondary surgery, and time interval between primary palatoplasty and secondary surgery. Postoperative speech outcomes were assessed at least 1 year after the secondary surgery and classified as velopharyngeal competence (VPC) or VPI. Variables were analyzed using multivariate logistic regression analysis, and the area under the curve (AUC) was used to validate model accuracy. The study sample comprised 101 patients. Of the patients, 62 had VPC and 39 had VPI after secondary surgery. The results showed a younger age at secondary surgery, a smaller velopharyngeal gap, being female, having a coronal velopharyngeal closure pattern and a velopharyngeal closure ratio of 90% or greater produced a greater probability of VPC. Given the constraints of this study, it appears that the Furlow palatoplasty should be prioritized when the clinical model predicts a substantial likelihood of VPC post-surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases and Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
- West China Second University Hospital, Sichuan University, Chengdu, China.
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases and Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China. Elect…
Förderung
- Sichuan Province Science and Technology Support Program
- National Natural Science Foundation of China
Zitieren
APA
Huang, Z., Bo, Z., Li, J., Zheng, Q., Shi, B., & Zeng, N. (2024). Proposed clinical model for predicting speech outcomes in patients undergoing Furlow palatoplasty for velopharyngeal insufficiency after primary palatoplasty. Journal of Cranio-Maxillofacial Surgery. https://doi.org/10.1016/j.jcms.2023.12.007
Vancouver
Huang Z, Bo Z, Li J, Zheng Q, Shi B, Zeng N. Proposed clinical model for predicting speech outcomes in patients undergoing Furlow palatoplasty for velopharyngeal insufficiency after primary palatoplasty. Journal of Cranio-Maxillofacial Surgery. 2024. doi:10.1016/j.jcms.2023.12.007
BibTeX
@article{Huang2024,
author = {Huang, Zhongping and Bo, Zhenyan and Li, Jingtao and Zheng, Qian and Shi, Bing and Zeng, Ni},
title = {Proposed clinical model for predicting speech outcomes in patients undergoing Furlow palatoplasty for velopharyngeal insufficiency after primary palatoplasty},
journal = {Journal of Cranio-Maxillofacial Surgery},
year = {2024},
doi = {10.1016/j.jcms.2023.12.007}
}
EUVIMED